Genexine, Inc. announced positive topline results from the multi-center, randomized, open-label, active-controlled pivotal phase 3 study (CTJ101PGHD301) being conducted in China to evaluate the efficacy and safety of eftansomatropin alfa (Genexine's proprietary long-acting growth hormone, also known as GX-H9) in children with growth hormone deficiency. The study being conducted by Genexine's partner in China, I-Mab, met its primary endpoint of annualized heightocity (AHV) at week 52 and demonstrated that eftansomatropin Alfa was non-inferior to Norditropin®. Eftansomatropin alFA was given by weekly injection vs.

Norditropin® given by daily injection. The mean AHV was 10.76 (cm/year) for eftansomatropinAlfa vs. 10.28 (cm/year) for Norditropin®, with a difference of 0.47 [95% CI -0.06,1.00] and non-inferiority p-value About EftansomatropinAlf.

GX-H9 has been developed utilizing Genexine's hyFc®? platform as a treatment for growth hormone deficiency (GHD). Patient compliance has been dramatically improved, which is critical for the pediatric population.

GX-H9 is being co-developed with Handok under a strategic partnership and with I-Mab for development in greater China. I-Mab has partnered with Jumpcan for product launch and commercialization of eftansomatrop in China.